Rhythm Pharmaceuticals, Inc.
RYTM
Rang in Aktien
#3069
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aktienkurs
$86.36
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$5.95B
Veränderung (1 Tag)
-1.83%
Veränderung (1 Jahr)
-21.69%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategorie
Healthcare
Operative Marge für Rhythm Pharmaceuticals, Inc. (RYTM)
Operative Marge zum October 2026 TTM: -83.62%
Laut den neuesten Finanzberichten und dem Aktienkurs von Rhythm Pharmaceuticals, Inc. beträgt die aktuelle operative Marge (TTM) -83.62%. Am Ende des Jahres 2023 lag die operative Marge bei -238.10%.
Historie der operativen Marge von Rhythm Pharmaceuticals, Inc. von 2012 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -83.62% | -59.02% |
| 2024 | -204.04% | -14.30% |
| 2023 | -238.10% | -68.59% |
| 2022 | -757.92% | -85.94% |
| 2021 | -5,391.85% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -100.46% |
US
|
|
| -149.01% | -98.22% |
US
|
|
| 25.57% | -100.31% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.34% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.